Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leading industry insight at your fingertips

Video, audio, and proprietary data sets br ing our articles and analyses to life.

Numerous search filters allow for precise content targeting, and articles and searches can be saved and shared with one-click

Set custom email alerts on any topic or search criteria so you never miss what you need to know most.




Phone (US): +1 212-520-2765
Phone (UK & Europe): +44 (0) 20 7017-4191

Subscribe today and get access to:

  • Real-time analysis accessible on mobile, tablet and PC.
  • Regular, detailed updates on policies coming out of FDA, the EU, OUS and bodies focused on global harmonization.
  • Analysis of regulatory/policy themes and interviews with key decision makers and experts.
  • Regulatory Developments: Including approvals, compliance and enforcement data, regulatory documents and other data.
  • Deep analysis and opinion offered around key regulatory events.
  • Company Developments: Including M&A, deals, financial results, partnerships and more.
  • Product Developments: Including clinical trial results, approvals, launches, postmarketing updates so you can drive your own new product strategy.
  • In-depth profiles of leading-edge companies assessing new trends and technologies.
  • Create email alerts tailored to your needs and refine using faceted search.
  • My View, a custom home page that follows your topics of interest.
  • “Ask the Analyst” exclusive client service to find out more about market access topics, developments, or trends to support presentations, proposals, or business critical decisions where your credibility is on the line.